title: Effect of chemotherapy with or without buserelin on serum hormone levels in premenopausal women with breast cancer.
abstract: Serial determinations of serum oestradiol (E2), follicle-stimulating hormone (FSH) and luteinising hormone (LH) were done to assess the effect of chemotherapy, with or without a gonadotropin-releasing hormone analogue, buserelin, on ovarian function in 147 premenopausal women treated for breast cancer. Cyclophosphamide, doxorubicin and 5-fluorouracil (CAF) plus buserelin was given to 81 women with metastatic disease, and 66 women were randomised to adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) with buserelin or CMF alone. Baseline mean E2 of patients treated with cytostatics plus buserelin fell from premenopausal levels and remained low while patients were on study. E2 levels remained at premenopausal values in patients treated with CMF alone. Downregulation of FSH and LH occurred with cytostatics plus depot buserelin, but fluctuated with the nasal administration; on CMF alone, FSH and LH levels increased. Buserelin plus cytostatics more effectively caused ovarian ablation than cytostatic treatment alone. Depot buserelin was more effective than nasal buserelin.
authors.affiliation: Department of Medical Oncology, University of Pretoria, South Africa.
authors.forename: C I
authors.initials: CI
authors.lastname: Falkson
authors.forename: H C
authors.initials: HC
authors.lastname: Falkson
authors.forename: G
authors.initials: G
authors.lastname: Falkson
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000097:blood* / Q000188:drug therapy* / Q000503:physiopathology; D002064:Buserelin / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004958:Estradiol / Q000097:blood*; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D005640:Follicle Stimulating Hormone / Q000097:blood*; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood*; D008598:Menstruation / Q000187:drug effects; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D010053:Ovary / Q000503:physiopathology; D013997:Time Factors
chemical_list: D004958:Estradiol; D004317:Doxorubicin; D003520:Cyclophosphamide; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D002064:Buserelin; D005472:Fluorouracil; D008727:Methotrexate